Literature DB >> 15006006

Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults.

Edwin A Bronsky1, Jay Grossman, Marc J Henis, Paul P Gallo, Umit Yegen, Giovanni Della Cioppa, John Kottakis, Sunil Mehra.   

Abstract

OBJECTIVE: To assess the peak inspiratory flow rate (PIFR) and forced inspiratory vital capacity (FIVC) through the formoterol (Foradil*) Aerolizer* in patients with mild, moderate and severe asthma. RESEARCH DESIGN AND METHODS: PIFR and FIVC were assessed in 33 adults and 32 children using a spirometer alone (baseline), a spirometer with an adaptor, and a spirometer with an adaptor and the Aerolizer inhaler (placebo loaded).
RESULTS: Of adult patients using the Aerolizer inhaler, 73% had PIFR values of >100 l/min and 91% had values of >60 l/min. PIFR in adults was reduced from a mean baseline of 283 l/min to 118 l/min through the loaded Aerolizer inhaler. Similarly, 75% of children using the Aerolizer inhaler had PIFR values >80 l/min and 91% had values of > 60 l/min. The mean PIFR in children was reduced from a baseline of 154 l/min to 100 l/min through the loaded Aerolizer inhaler. Only small mean decreases from baseline were observed in FIVC through the loaded Aerolizer inhaler: 8.4% in adults and 3.8% in children. FIVC values of > 2.0 litre were achieved in 82% of adults, and 81% of children achieved FIVC values of >1.5 litre.
CONCLUSIONS: This study, albeit in a relatively small patient population, suggests that most children and adults with asthma can generate PIFRs of > 60 l/min and FIVCs of > 1.5 litre through the Aerolizer inhaler regardless of their disease severity. Such findings compare extremely favourably with other dry powder inhalers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006006     DOI: 10.1185/030079903125002793

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  7 in total

1.  Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying.

Authors:  Suzanne M D'Addio; John Gar Yan Chan; Philip Chi Lip Kwok; Bryan R Benson; Robert K Prud'homme; Hak-Kim Chan
Journal:  Pharm Res       Date:  2013-07-27       Impact factor: 4.200

2.  Multi-scale modelling of powder dispersion in a carrier-based inhalation system.

Authors:  Zhenbo Tong; Hidehiro Kamiya; Aibing Yu; Hak-Kim Chan; Runyu Yang
Journal:  Pharm Res       Date:  2014-12-17       Impact factor: 4.200

3.  Dry powder aerosols to co-deliver antibiotics and nutrient dispersion compounds for enhanced bacterial biofilm eradication.

Authors:  S Sommerfeld Ross; S Gharse; L Sanchez; J Fiegel
Journal:  Int J Pharm       Date:  2017-08-04       Impact factor: 5.875

4.  A randomised, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma.

Authors:  Katayoon Najafizadeh; Hamid Sohrab Pour; Mojtaba Ghadyanee; Masoud Shiehmorteza; Masoud Jamali; Sayeed Majdzadeh
Journal:  Emerg Med J       Date:  2007-05       Impact factor: 2.740

Review 5.  Regular treatment with formoterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Matthew J Cates
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

6.  Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.

Authors:  David Prime; Wilfried de Backer; Melanie Hamilton; Anthony Cahn; Andrew Preece; Dennis Kelleher; Amanda Baines; Alison Moore; Noushin Brealey; Jackie Moynihan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2015-09-15       Impact factor: 2.849

7.  Performance of dry powder inhalers with single dosed capsules in preschool children and adults using improved upper airway models.

Authors:  Sandra Lindert; Antje Below; Joerg Breitkreutz
Journal:  Pharmaceutics       Date:  2014-02-06       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.